Paul Carter
Director/Miembro de la Junta en HUTCHMED (CHINA) LIMITED .
Fortuna: 742 759 $ al 31/05/2024
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Anthony Tennyson | M | - | 4 años | |
| Murray Stewart | M | 63 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 21 años |
| Per Lundin | M | 41 |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 años |
| John F. Donovan | M | - |
Concentric Analgesics, Inc.
 Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 años |
| Craig O. Husfeld | M | - |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 años |
| Jonathan Held | M | 38 | 4 años | |
| Frank J. Bellizzi | M | 58 |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 años |
| Thomas Woiwode | M | 52 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 años |
| John McHutchison | M | 66 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 13 años |
| Wei Guo Su | M | 66 | 19 años | |
| Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 años |
| Stephen P. Squinto | M | 67 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 años |
| Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 años |
| Sandipkumar S. Kapadia | M | 54 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 años |
| Edith Shih | F | 71 | 24 años | |
| Harpreet Singh-Jasuja | M | 50 | 24 años | |
| Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 años |
| John Papastergiou | M | - | 3 años | |
| George Scorsis | M | - | 4 años | |
| Steffen Walter | M | 47 | 4 años | |
| Matthew Wood | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 años |
| Andrew Dickinson | M | 54 | 8 años | |
| Mark Lee | M | 46 | - | |
| Michael Atieh | M | 70 | 4 años | |
| Bryan Reasons | M | 56 | 5 años | |
| Shu Kam Mok | M | 63 | 7 años | |
| Derek Belz | M | - | 2 años | |
| Chig Fung Cheng | M | 57 | 16 años | |
| Stephen Page | M | - | 3 años | |
| Dan Eldar | M | 70 | 8 años | |
| Graeme Jack | M | 73 | 7 años | |
| Heather Mason | F | 63 | 4 años | |
| Thomas King | M | 69 |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 7 años |
| James Ford | M | - | 29 años | |
| Karen Atkin | M | 58 | 3 años | |
| Selina Zhang | F | - | 2 años | |
| Michael Shi | M | 59 | 2 años | |
| Maria Poulada | F | - | 11 años | |
| Claudia Blattner | M | - | 9 años | |
| Cedrik M. Britten | M | 49 | 4 años | |
| Sarah Gordon-Wild | F | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Amrit Nagpal | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Roger K. Cady | M | - | 8 años | |
| Carsten Reinhardt | M | 57 | 4 años | |
| Adam Stoten | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 años |
| Ling Yang | F | 44 | 1 años | |
| Arun Dhandayudham | M | - | 2 años | |
| Mathias Hothum | M | 58 | 1 años | |
| Arnd Christ | M | 57 | 4 años | |
| Toni Weinschenk | M | 51 | 4 años | |
| Eliot Forster | M | 58 | 4 años | |
| Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
| Graham Rivers | M | - | 26 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Mark Litton | M | 56 | 14 años | |
| Randall Schatzman | M | 69 | 14 años | |
| Alan Montgomery | M | 70 | 13 años | |
| Matthew Harbaugh | M | 53 | 6 años | |
| Jeremy Charles Green | M | 49 | - | |
| Benjamin Sessa | M | - | - | |
| Paul Cleveland | M | 67 | - | |
| Kevin Chow | M | 54 | 7 años | |
| Robert Azelby | M | 56 | 1 años | |
| Christian Hogg | M | 58 | 16 años | |
| Mark Trudeau | M | 62 | 9 años | |
| Melissa Yeager | F | - | 10 años | |
| Angus Russell | M | 68 | 8 años | |
| John Latham | M | 64 | 15 años | |
| Antonin Rollet de Fougerolles | M | 59 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| David Walsey | M | - | - | |
| Daniel A. Celentano | M | 72 | 1 años | |
| Larry K. Benedict | M | 63 | 11 años | |
| Christopher Huang | M | 72 | 11 años | |
| Scott Applebaum | M | 57 | - | |
| Riad El-Dada | M | 59 | 1 años | |
| Gordo Whittaker | M | - | - | |
| Kate Butler | F | - | 5 años | |
| Richard Whitley | M | 78 | 13 años | |
| Gordon Earle Moore | M | 95 | 17 años | |
| Peter Bisgaard | M | 50 | 3 años | |
| Clay Siegall | M | 63 | 14 años | |
| Woodrow Myers | M | 70 | 1 años | |
| JoAnn Reed | F | 68 | 9 años | |
| J. Carroll | M | 74 | 9 años | |
| H. Culp | M | 60 | 9 años | |
| Melvin Booth | M | 79 | 5 años | |
| Kneeland Youngblood | M | 69 | 9 años | |
| James Sulat | M | 73 | 1 años | |
| Paul Bisaro | M | 63 | 1 años | |
| Robert Wilson | M | 81 | 11 años | |
| Gary Bridger | M | 61 | 3 años | |
| John David Coombe | M | 79 | 5 años | |
| Neal Goldman | M | 54 | 1 años | |
| Stephen M. Dow | M | 68 | 13 años | |
| Wendy Yarno | F | 68 | - | |
| Deepa Pakianathan | M | 59 | 6 años | |
| Michael William Davis Howell | M | 76 | 11 años | |
| Diane Gulyas | F | 67 | 5 años | |
| Chi Keung To | M | 72 | 24 años | |
| David Carlucci | M | 69 | 9 años | |
| Patrick Malloy | M | - | - |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Reino Unido | 30 | 30.00% |
| Estados Unidos | 27 | 27.00% |
| Hong-Kong | 15 | 15.00% |
| Alemania | 12 | 12.00% |
| Suiza | 10 | 10.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Paul Carter
- Red Personal
